<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292252</url>
  </required_header>
  <id_info>
    <org_study_id>UCSFSpineForteo</org_study_id>
    <nct_id>NCT01292252</nct_id>
  </id_info>
  <brief_title>Use of Forteo (Teriparatide) in Posterolateral Lumbar Spine Fusion</brief_title>
  <official_title>Assessment of the Efficacy of Forteo (Teriparatide) in Patients Undergoing Posterolateral Lumbar Spinal Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shane Burch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of 12 weeks of daily treatment with&#xD;
      teriparatide on spine fusion in adult patients who are undergoing multi-level posterolateral&#xD;
      spine fusion surgery for degenerative conditions of the lumbar spine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients undergoing spine fusion surgery, non-fusion (or pseudarthrosis) is one of the&#xD;
      major complications that can lead to poor clinical outcomes. Therefore, treatments that&#xD;
      promote or augment fusion are highly desirable. Teriparatide (Forteo, recombinant human&#xD;
      parathyroid hormone [1-34]) is a systemically administered peptide hormone that is&#xD;
      FDA-approved for the treatment of osteoporosis in postmenopausal women or other populations&#xD;
      at high risk for fracture. While teriparatide has been shown to enhance spinal fusion in&#xD;
      several rodent and rabbit studies, no clinical studies to date have examined its effect on&#xD;
      spinal fusion in humans. While Forteo is FDA approved, and IND is required for this trial to&#xD;
      study an unapproved indication: Posterolateral Lumbar Spine Fusion.&#xD;
&#xD;
      This single-site two-year prospective randomized double-blind placebo-controlled study is&#xD;
      designed to examine the effects of peri-operative teriparatide treatment in older adults&#xD;
      undergoing multi-level posterolateral lumbar spine fusion. All eligible patients seen at the&#xD;
      UCSF Spine Center will be invited to enroll in the study. Upon enrollment, patients will have&#xD;
      screening labs drawn in conjunction with their routine pre-operative work-up, to include&#xD;
      complete blood count (CBC), chemistry panel including calcium level, liver function tests&#xD;
      (LFTs) including alkaline phosphatase, parathyroid hormone (PTH) level, and 25-hydroxyvitamin&#xD;
      D level. If eligible after screening labs are completed, they will be scheduled for bone&#xD;
      density (DEXA) scan and be randomized in a 2:1 ratio to receive daily subcutaneous injections&#xD;
      of teriparatide 20 ug/d or placebo. The total duration of treatment will be 12 weeks, with&#xD;
      two weeks pre-operative and 10 weeks post-operative treatment.&#xD;
&#xD;
      Patients will be scheduled to attend all standard post-operative follow-up clinic visits,&#xD;
      which will be at 6 weeks, 3 months, 6 months, and 12 months after surgery. At 3 months post&#xD;
      operative visit, patients will have lab drawn for calcium. At each follow-up visit, AP and&#xD;
      lateral x-ray radiographs will be taken of the lumber spine to assess progression of bone&#xD;
      healing and positioning of any hardware placed. Participants will be asked to complete a pain&#xD;
      Visual Analog Score (VAS), European Quality of Life-5 Dimensions (EQ-5D), and Oswestry&#xD;
      Disability Index (ODI) questionnaire at each visit for assessment of clinical outcomes.&#xD;
      Thin-section helical CT scans of the lumbar spine will be taken at 12 months after surgery&#xD;
      for definitive assessment of fusion. All radiographs will be evaluated by a blinded panel of&#xD;
      three reviewers including a radiologist and a spine surgeon to assess primary outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Spine Fusion, Measured by the Number of Participants With Complete Spine Fusion at 1 Year</measure>
    <time_frame>One year</time_frame>
    <description>Quality of spine fusion, measured by the number of participants with complete spine fusion at 1 year. Spine fusion at one year was assessed using thin-section helical computed tomography (CT) scan of the lumbar spine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Spine Fusion</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes Measured by: Visual Analog Score (VAS), European Quality of Life - 5 Dimensions (EQ-5D) and Oswestry Disability Index (ODI) Scores at 1 Year</measure>
    <time_frame>One year</time_frame>
    <description>The self-reported pain Visual Analog Score (VAS), the score range is 0-100 with higher scores indicating more pain.&#xD;
European Quality of Life - 5 Dimensions (EQ-5D) is a standardized instrument for measuring generic health status, the scale range is from 0.000 (death) to 1.000 (perfect health).&#xD;
Oswestry Disability Index (ODI) provides information about how back or leg pain is affecting the ability to manage in everyday life, the points range from 0-50, which is doubled and reported as a percentage. Higher scores indicate higher disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects</measure>
    <time_frame>One year</time_frame>
    <description>Number of participants with serious adverse events and other (not including serious) adverse events at one year are reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Lumbar Spondylosis</condition>
  <condition>Lumbar Spondylolisthesis</condition>
  <condition>Adult Degenerative Lumbar Scoliosis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Forteo, Terapeptide 20 ug subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>teriparatide</intervention_name>
    <description>Teriparatide 20 ug subcutaneous injection daily for 12 weeks</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Forteo</other_name>
    <other_name>recombinant human parathyroid hormone (1-34)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline solution</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 60-90 years with lumbar spondylosis, spondylolithesis, or adult&#xD;
             degenerative scoliosis, including disc pathology, stenosis, deformity, instability, or&#xD;
             postdecompression revision, who are scheduled to undergo three-level or greater&#xD;
             posterolateral lumbar spinal fusion.&#xD;
&#xD;
          -  Willing and able to use a pen-type delivery system to administer daily subcutaneous&#xD;
             injections.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of bone morphogenic protein (BMP) posterolaterally during the fusion procedure.&#xD;
&#xD;
          -  Previous spinal fusion at the intended fusion levels.&#xD;
&#xD;
          -  Prior use of Forteo (teriparatide).&#xD;
&#xD;
          -  Use of digoxin.&#xD;
&#xD;
          -  Paget's Disease of bone.&#xD;
&#xD;
          -  History of primary skeletal malignancy, presence of bone metastases, or previous&#xD;
             skeletal exposure to therapeutic irradiation.&#xD;
&#xD;
          -  Elevated serum calcium, serum PTH &gt;70 pg/ml, 25-hydroxyvitamin D &lt;12 ng/mL, or active&#xD;
             liver disease.&#xD;
&#xD;
          -  History of symptomatic nephro- or urolithiasis in the past two years.&#xD;
&#xD;
          -  History of malignant neoplasm in the past five years, except for superficial basal&#xD;
             cell carcinoma or squamous cell carcinoma.&#xD;
&#xD;
          -  Carcinoma in situ of the uterine cervix treated in the past year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shane Burch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Li</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Spine Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ucsfhealth.org/adult/medical_services/spine/index.html</url>
    <description>UCSF Spine Center</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 7, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2011</study_first_posted>
  <results_first_submitted>December 8, 2020</results_first_submitted>
  <results_first_submitted_qc>January 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2021</results_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Shane Burch</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scoliosis</mesh_term>
    <mesh_term>Spondylolisthesis</mesh_term>
    <mesh_term>Spondylosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
    <mesh_term>Parathyroid Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>714 patients were screened for the study between August 2011 and March 2016.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment: Forteo, Terapeptide 20 ug</title>
          <description>Forteo, Terapeptide 20 ug subcutaneous injection&#xD;
teriparatide: Teriparatide 20 ug subcutaneous injection daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Control: Saline Placebo</title>
          <description>Saline placebo&#xD;
Placebo: Saline solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment: Forteo, Terapeptide 20 ug</title>
          <description>Forteo, Terapeptide 20 ug subcutaneous injection&#xD;
teriparatide: Teriparatide 20 ug subcutaneous injection daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Control: Saline Placebo</title>
          <description>Saline placebo&#xD;
Placebo: Saline solution</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.0" spread="6.1"/>
                    <measurement group_id="B2" value="71.3" spread="6.3"/>
                    <measurement group_id="B3" value="70.5" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" spread="7.6"/>
                    <measurement group_id="B2" value="29.44" spread="6.4"/>
                    <measurement group_id="B3" value="28.48" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Analog Score (VAS)</title>
          <description>Visual Analog Score (VAS), the score range is 0-100 with higher scores indicating more pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.7" spread="9.6"/>
                    <measurement group_id="B2" value="15.2" spread="9.1"/>
                    <measurement group_id="B3" value="17.8" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>European Quality of Life - 5 Dimensions (EQ-5D)</title>
          <description>European Quality of Life - 5 Dimensions (EQ-5D) is a standardized instrument for measuring generic health status, the scale range is from 0.000 (death) to 1.000 (perfect health)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.57" spread="0.2"/>
                    <measurement group_id="B2" value="0.60" spread="0.2"/>
                    <measurement group_id="B3" value="0.58" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oswestry Disability Index (ODI)</title>
          <description>Oswestry Disability Index (ODI) provides information about how back or leg pain is affecting the ability to manage in everyday life, the points range from 0-50, which is doubled and reported as a percentage. Higher scores indicate higher disability.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.1" spread="16.1"/>
                    <measurement group_id="B2" value="46.4" spread="15.3"/>
                    <measurement group_id="B3" value="49.7" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quality of Spine Fusion, Measured by the Number of Participants With Complete Spine Fusion at 1 Year</title>
        <description>Quality of spine fusion, measured by the number of participants with complete spine fusion at 1 year. Spine fusion at one year was assessed using thin-section helical computed tomography (CT) scan of the lumbar spine.</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Forteo, Terapeptide 20 ug</title>
            <description>Forteo, Terapeptide 20 ug subcutaneous injection&#xD;
teriparatide: Teriparatide 20 ug subcutaneous injection daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control: Saline Placebo</title>
            <description>Saline placebo&#xD;
Placebo: Saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Spine Fusion, Measured by the Number of Participants With Complete Spine Fusion at 1 Year</title>
          <description>Quality of spine fusion, measured by the number of participants with complete spine fusion at 1 year. Spine fusion at one year was assessed using thin-section helical computed tomography (CT) scan of the lumbar spine.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Spine Fusion</title>
        <time_frame>One year</time_frame>
        <population>Data were not collected as intended and are not available to reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Forteo, Terapeptide 20 ug</title>
            <description>Forteo, Terapeptide 20 ug subcutaneous injection&#xD;
teriparatide: Teriparatide 20 ug subcutaneous injection daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control: Saline Placebo</title>
            <description>Saline placebo&#xD;
Placebo: Saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Spine Fusion</title>
          <population>Data were not collected as intended and are not available to reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Outcomes Measured by: Visual Analog Score (VAS), European Quality of Life - 5 Dimensions (EQ-5D) and Oswestry Disability Index (ODI) Scores at 1 Year</title>
        <description>The self-reported pain Visual Analog Score (VAS), the score range is 0-100 with higher scores indicating more pain.&#xD;
European Quality of Life - 5 Dimensions (EQ-5D) is a standardized instrument for measuring generic health status, the scale range is from 0.000 (death) to 1.000 (perfect health).&#xD;
Oswestry Disability Index (ODI) provides information about how back or leg pain is affecting the ability to manage in everyday life, the points range from 0-50, which is doubled and reported as a percentage. Higher scores indicate higher disability.</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Forteo, Terapeptide 20 ug</title>
            <description>Forteo, Terapeptide 20 ug subcutaneous injection&#xD;
teriparatide: Teriparatide 20 ug subcutaneous injection daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control: Saline Placebo</title>
            <description>Saline placebo&#xD;
Placebo: Saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes Measured by: Visual Analog Score (VAS), European Quality of Life - 5 Dimensions (EQ-5D) and Oswestry Disability Index (ODI) Scores at 1 Year</title>
          <description>The self-reported pain Visual Analog Score (VAS), the score range is 0-100 with higher scores indicating more pain.&#xD;
European Quality of Life - 5 Dimensions (EQ-5D) is a standardized instrument for measuring generic health status, the scale range is from 0.000 (death) to 1.000 (perfect health).&#xD;
Oswestry Disability Index (ODI) provides information about how back or leg pain is affecting the ability to manage in everyday life, the points range from 0-50, which is doubled and reported as a percentage. Higher scores indicate higher disability.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visual Analog Score (VAS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.67" spread="13.4"/>
                    <measurement group_id="O2" value="9.67" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>European Quality of Life - 5 Dimensions (EQ-5D)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.733" spread="0.19"/>
                    <measurement group_id="O2" value="0.708" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oswestry Disability Index (ODI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" spread="19.9"/>
                    <measurement group_id="O2" value="31.9" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effects</title>
        <description>Number of participants with serious adverse events and other (not including serious) adverse events at one year are reported.</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Forteo, Terapeptide 20 ug</title>
            <description>Forteo, Terapeptide 20 ug subcutaneous injection&#xD;
teriparatide: Teriparatide 20 ug subcutaneous injection daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Control: Saline Placebo</title>
            <description>Saline placebo&#xD;
Placebo: Saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects</title>
          <description>Number of participants with serious adverse events and other (not including serious) adverse events at one year are reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (Not Including Serious) Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment: Forteo, Terapeptide 20 ug</title>
          <description>Forteo, Terapeptide 20 ug subcutaneous injection&#xD;
teriparatide: Teriparatide 20 ug subcutaneous injection daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Control: Saline Placebo</title>
          <description>Saline placebo&#xD;
Placebo: Saline solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>rapid heart</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>altered mental state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection of surgical site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>shingles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>pain and burning at injection site</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shane Burch, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-353-4487</phone>
      <email>Shane.Burch@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

